Effects of SP500263, a novel, potent antiestrogen, on breast cancer cells and in xenograft models.
|
| Abstract |
We have compared the antitumor activities of SP500263, a novel next-generation selective estrogen receptor modulator (SERM), tamoxifen, and raloxifene side-by-side in in vitro and in vivo MCF-7 breast cancer models. In vitro, SP500263 acted as an antiestrogen and potently inhibited estrogen-dependent MCF-7 proliferation with IC(50) values in the nanomolar range. SP500263 also strongly inhibited MCF-7 proliferation in the absence of estrogen at all of the concentrations tested. To investigate the antitumor activity of SP500263 in animals, athymic nude mice were implanted with MCF-7 tumor in the presence of a tumor growth-supporting sustained release estrogen pellet. Treatment was initiated after tumors were established. SP500263, administered for 28 days through daily i.p. dosing, effectively reduced estrogen-stimulated tumor growth at 3 and 30 mg/kg. SP500263 was as efficacious as tamoxifen and superior to raloxifene at the corresponding doses. Maximum efficacy was reached with the 30 mg/kg dose. The observed effects were highly significant. SP500263 represents a member of a novel series of SERMs that is structurally unrelated to SERMs currently on the market or in clinical development. The experiments described herein demonstrate that SP500263 is efficacious in the MCF-7 proliferation assay and in a murine model of breast cancer.
|
|---|---|
| Authors | Helen Brady, Sonal Desai, Leah M Gayo-Fung, Sak Khammungkhune, Jeffrey A McKie, Eoin O'Leary, Laura Pascasio, May Kung Sutherland, David W Anderson, Shripad S Bhagwat, Bernd Stein |
| Journal | Cancer research (Cancer Res) Vol. 62 Issue 5 Pg. 1439-42 (Mar 01 2002) ISSN: 0008-5472 [Print] United States |
| PMID | 11888917 (Publication Type: Journal Article) |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!